Damage to peripheral nerves triggers a cascade of events in axotomized sensory neurones that are generally believed to be responsible for the generation of neuropathic pain. Recent data in animal models show that alterations in the properties of undamaged neurones that project into a damaged nerve can also play an important role. These new findings could explain some of the enigmatic clinical signs and symptoms of pain following nerve injury such as the spread of symptoms into areas not affected by the primary lesion. The basis by which uninjured nerves could be affected is a reduced supply of neurotrophic factors, an abnormal interaction in the Remak bundles of partially denervated Schwann cells and unmyelinated axons, or the byproducts of Wallerian degeneration.
Introduction
The International Association for the Study of Pain de®nes peripheral neuropathic pain as pain following a primary lesion or dysfunction of the peripheral nervous system [1] . However, the suitability of this de®nition has recently been debated.
The clinical presentation of pain symptoms can be similar in patients with demonstrable lesions of major peripheral nerves or conditions that do not involve obvious damage to the nervous system. For example, a patient with complex regional pain syndrome (CRPS) type I (previously also described as re¯ex sympathetic dystrophy) in an arm secondary to an orthopaedically uncomplicated fracture might have some painful symptoms and signs (hyperalgesia, trophic changes) similar to those of another patient with a partial brachial plexus injury. Both conditions would ful®l the broad diagnostic International Association for the Study of Pain criteria for neuropathic pain, given the presence of dysfunction of the nervous system as in CRPS or a primary neural lesion. Moreover, the uncritical combination of a wide range of conditions under one umbrella term is made worse by the tendency to label painful conditions as neuropathic pain' if they have proved refractory to standard analgesic treatment. Patients whose condition has been labelled on the basis of treatment failure may, however, harbour potentially remediable causes, emphasizing the need for careful diagnostic assessment and review in patients with such pain.
The distinction between painful conditions with or without lesions of major peripheral nerves is also supported by a large body of work in animal models of neuropathic, in¯ammatory or cancer pain [2 . ,3,4 . ,5
. .
,6]. This work has shown profound qualitative differences in the molecular, cellular and functional properties of the peripheral and central neuronal pathways involved in nociception.
A more restrictive de®nition of neuropathic pain is also not without its problems, however. First, clinical examination and electrodiagnostic tests may fail to detect nerve lesions. For example, trigeminal neuralgia is commonly classi®ed as neuropathic pain on clinical grounds, even though nerve damage cannot in most cases be formally veri®ed. Another example is patients with restless legs syndrome who may suffer from a profound small ®bre sensory loss, as evidenced by skin biopsies, but which would pass unnoticed in conventional diagnostic tests [7 . ]. Second, tissue trauma will almost always result in damage to nerve terminals, but the point at which a lesion has to be along the proximo-distal projection of a sensory neurone and how severe the damage must be before neuropathic pain appears is at present unclear. Finally, neuropathic pain and non-neuropathic pain share some fundamental mechanisms. Thus, N-methyl-D-aspartate (NMDA)-receptor-mediated central sensitization plays an important role in the development of mechanical hypersensitivity, notably brush-evoked pain in chronic pain states, irrespective of whether they are caused by nerve damage or tissue in¯ammation.
Animal models and mechanisms
Recent studies in animal models of partial nerve injury suggest that the site of the lesion along the peripheral course of a sensory neurone is indeed an important factor in the manifestations of neuropathic pain (Fig. 1) . Lesions distal to the cell soma will lead to various degrees of Wallerian degeneration depending on where the lesion occurs. Partial lesions of the sciatic nerve or transection of a spinal nerve will trigger, for example, in®ltration of macrophages and reactive changes of denervated Schwann cells in the distal projections of those nerves. This may explain why some changes of sensory neurone function can even be found in neurones that have not been axotomized.
One commonly used model of neuropathic pain is the lesion of the L5 spinal nerve [8] . Studies have now shown that a host of neurochemical changes can also be found in the ipsilateral dorsal root ganglion L4 [9] that does not contain lesioned neurones, but cells which project to the same nerve or to overlapping distal innervation territories that are supplied by the neurones in the L5 DRG. It is likely that some Remak bundles contain both axotomized and non-axotomized neurones. (Fig. 2) .
In addition to the discharge of unmyelinated nociceptors that is generated peripherally, the cell bodies of myelinated axons develop a discharge. Some of this activity is generated by nonlesioned, possibly nociceptive neurones innervating skeletal muscle that have their cell body in ganglia that contain axotomized neurones [20 . . ], or indeed in neurones that are in adjacent ganglia [21
. . ]. There is also a subpopulation of axotomized neurones whose cell bodies in the ganglion develop ectopic activity following spinal nerve lesion [22, 23] . The magnitude of this discharge is dependent on changes in local blood¯ow and increases during periods of vasoconstriction [22] . There is also evidence that this discharge can originate in some neurones from high frequency oscillations of TTX-sensitive sodium currents in non-nociceptive neurones that reach threshold for action potential generation [24] . Indeed, studies have shown a strong upregulation of the messenger RNA that encodes the type III embryonic sodium channel (Nav1.3); this is probably responsible for the appearance of a rapidly repriming sodium current that is normally absent in adult sensory neurones [21 . . ,25]. Interestingly, changes in the expression pattern of sodium channels, the electrophysiological changes and the nociceptive behaviour were reversed by the application of glial cell line derived neurotrophic factor (GDNF) [21 . . ]. Thus, the properties of nonaxotomized sensory neurones can be profoundly affected in models of neuropathic pain, and this illustrates some of the dilemmas for the de®nition of neuropathic pain.
Therapy
Although the treatment options for neuropathic pain are still limited, the effectiveness of available drugs has been summarized by several excellent reviews [26±31]. Treatment trials have mainly been carried out in patients suffering from postherpetic neuralgia, diabetic polyneuropathy or HIV-related neuropathy. Comparisons of the effectiveness between different drugs can be made on the basis of the numbers needed to treat (NNT) to obtain useful pain relief (often de®ned as 50% reduction in the magnitude of pain; Table 1 ) [27] . However, a problem with meta-analysis is that many studies include small numbers of patients, which tend to overestimate treatment ef®cacy by as much as 30% [32] . Conversely, some studies may have too little power to detect statistical signi®cant differences. Very few studies have used parallel group design and some of the most commonly used drugs such as the classical anticonvulsants phenytoin and carbamazepine have only been evaluated in few controlled trials that enrolled a small number of patients. On the basis of meta-analysis, tricyclic antidepressants continue to be among the most effective treatments in many neuropathic pain states. However, notable exceptions are two trials with parallel group or factorial design [33, 34] , which enrolled more than 100 patients with HIV-related neuropathy each, whose results showed no bene®t of amitriptyline. The apparent lack of ef®cacy of amitriptyline in HIV-associated distal sensory neuropathy cannot easily be explained at the moment, but an understanding of this discrepancy with other neuropathies may shed some light on the mode of action of tricyclic antidepressants. Sites at which ectopic discharge is generated after a lesion to the L5 spinal nerve or its branches The ef®cacies of tramadol or gabapentin appear to be less than that of tricyclic antidepressants. Although frequently prescribed, the use of classical anticonvulsant drugs is endorsed by only few studies many of which appear to have major¯aws. Sympathetic blocks, which were long regarded as standard treatment for some forms of CRPS (type 2, formerly known as causalgia), have only recently been subjected to controlled trials, most of which failed to prove ef®cacy [31] .
Commonly used drugs
a-Lipoic acid a-Lipoic acid has been used for the treatment of diabetic neuropathy. A large study in over 300 patients [35] showed a reduction of pain intensity during daily intravenous application of a-lipoic acid (NNT 4.3, 95% con®dence interval 2.6±11.3 for 600 and 1200 mg/day). However, a subsequent, multicentre trial including more than 500 patients [36] showed that a 3-week course of intravenous treatment followed by a 6-month period of oral treatment had no effects on neuropathic symptoms that were distinguishable from those of placebo. Several long-term trials are currently underway to re-examine the ef®cacy of this drug [37] .
Novel drugs and delivery systems
Because of the largely unmet clinical need and a better understanding of the pathophysiological mechanisms that contribute to neuropathic pain, there has been an increasing number of treatment trials using novel drugs or delivery systems.
Topical lidocaine patches have been ef®cacious in reducing the pain of postherpetic neuralgia [38, 39] . A positive effect was also recently shown in a small, openlabel, prospective study of 16 patients who suffered from neuropathic pain other than postherpetic neuralgia [40] . Capsaicin creams have been used in several studies. Although many of them were nominally placebocontrolled, the burning sensation following application of the drug usually unblinded patient and observer. One recent placebo-controlled study [41] reported that there was an average decrease of approximately 15% of the magnitude of pain with topical 0.025% capsaicin cream, a cream that contained 3.3% doxepin, or a combination of both. This suggests that a topical treatment could be of use when symptoms are restricted to a small area. Because all of these drugs need to be given on a longterm basis, side-effect pro®les are at least as important as the magnitude of the antihyperalgesic effect in selecting drugs for an individual.
There have been also a number of studies that failed to show ef®cacy for the treatment of neuropathic pain. No ef®cacy was found for 100 or 200 mg/day riluzole in a study including more than 40 patients [42] . Similarly, lanepitant, a nonpeptidergic antagonist for the neurokinin-1 (substance P) receptor, failed to show ef®cacy in a study of 93 patients with painful diabetic neuropathy [43] , which is similar to earlier negative ®ndings with use of other substance P antagonists in treating neuropathic pain [44] . The results from several studies with different substance P antagonists agree with a recent analysis of mutant mice lacking the neurokinin-1 receptor [45] , which failed to show differences of pain behaviour to wild-type mice in models of neuropathic pain.
In contrast to the ef®cacy of many different antidepressant drugs, St. John's wort, which also has antidepressant actions, showed no analgesic ef®cacy in a trial of 47 patients with painful neuropathy of mixed aetiology [46] .
In contrast to the pain relief provided by some anticonvulsants, two placebo-controlled studies using lamotrigine showed no ef®cacy. These includes one study in which lamotrigine was titrated to 300 mg/day in a trial of 42 patients with painful HIV-associated distal sensory neuropathy [47] and another study of 100 patients with neuropathic pain of different aetiologies that used a dose escalation to 200 mg/day lamotrigine [48] .
A large body of experimental evidence in animal models of neuropathic pain suggests a crucial role of the activation of NMDA receptors [2 . ], and studies using intravenous infusion of the NMDA receptor antagonist ketamine have shown a reduction in the magnitude of pain in humans with neuropathic pain at the expense of a high incidence of side-effects [49, 50] . These encouraging results have led to attempts to harness orally bioavailable drugs with NMDA-blocking activity for the treatment of neuralgia. Positive effects were seen in a small trial using dextromethorphan in a group of patients with neuropathic pain in limbs and trunk of mixed aetiology [51] ; the average dose was 380 mg/day (NNT 1.9, 95% con®dence interval 1.1±3.7; 26 patients). However, more recent studies have failed to show the same effect for cranial neuralgias [52] . Moreover, another study with memantine found no bene®t over placebo [53] .
Nerve growth factor is crucial for the development and maintenance of small myelinated or unmyelinated sensory neurones, most of which have nociceptive function [54] . Two large studies used subcutaneous administration of recombinant human nerve growth factor to study long-term ef®cacy to revert symptoms and progression of small-®bre neuropathies. A study of over 1000 diabetic patients [55] failed to show any ef®cacy, and the small effects on pain relief observed in a study that enrolled more than 250 patients with HIVrelated neuropathy [56] lost signi®cance when the results of patients that became unblinded during the trial were excluded.
Given that oral drug treatment of neuropathic pain is still unsatisfactory, other treatment modalities have been tried in patients suffering from postherpetic neuralgia. One of the problems in studying prophylactic or therapeutic interventions in herpes zoster and postherpetic neuralgia is the variable incidence of pain between studies and some uncertainty regarding the natural history of the disease. Recent studies have shown that the risk of neuralgia after herpes zoster may be lower than previously estimated. The incidence of zoster in a general immunocompetent population is approximately 0.2% in persons younger than 50 years, but increases to 1% in those older than 80 years [57] . There is no universally agreed de®nition regarding the time following healing of the acute herpes rash at which the pain is considered to be postherpetic neuralgia, but studies of antiviral therapy usually chose the 3-month time point [58] . The risk of postherpetic neuralgia also increases with age [57] , and data collected from patients in the placebo-arm of antiviral trials of herpes zoster show that pain is present in approximately 10±20% of individuals at 3±6 months [59] . Recent prospective studies have shown that the incidence of postherpetic pain continuously decreases to low numbers over the ®rst year after herpes zoster. In one study conducted in over 400 patients [60] pain was present at 3 months in less than 2% of patients younger than 60 years, but in 10% of individuals above that age. After 1 year none of the patients in the younger age group reported severe pain and the percentage had dropped to 3% in the older patient group. In one study of over 100 patients [61, 62 . ] more than 90% of patients reported pain during the acute skin eruption, but pain and hyperalgesia were present in 25% of the patients at 3 months and in 12% at 6 months. Given the progressive reduction in pain after herpes zoster, adequate controls in study protocols appear to be particularly important.
Two recent studies that enrolled several hundred patients each reported astonishing effects of intrathecal or epidural application of steroids. One study [63] investigated the incidence of postherpetic neuralgia in 230 patients treated either intravenously with aciclovir and prednisolone for 21 days or with epidural injections of bupivacaine and methylprednisolone through an indwelling catheter for 7±21 days. The incidence of pain 1 year after the eruption of herpes zoster was approximately 20% in the group that received intravenous treatment, but only 2% in patients that had received epidural injections.
In another study [64 . . ], 277 patients with postherpetic neuralgia for at least 1 year were randomly assigned to receive either intrathecal injections of a combination of methylprednisolone and lidocaine, or lidocaine alone once per week for up to 4 weeks, or no treatment. Pain was evaluated before randomization, at the end of the treatment period, and then 4 weeks, 1 year and 2 years later. Whereas the no-treatment group and the group that received lidocaine alone showed no signi®cant reduction in the magnitude of pain, there was a profound and lasting reduction in the average pain score (rated on a 0±100 visual analogue scale) in patients receiving the methylprednisolone with lidocaine, from an average of about 75% to approximately 20%. More than 90% of patients in this treatment arm reported excellent or good pain relief as compared with less than 10% in the group that received lidocaine only. One of the surprising results of that study was the reported absence of severe adverse events such as arachnoiditis following injection of methylprednisolone or the side-effects of a transient spinal anaesthesia after intrathecal instillation of lidocaine.
Given that postherpetic neuralgia affects an older patient population the safest approach appears to be application of lidocaine patches, followed by a tricyclic antidepressant such as nortryptyline or gabapentin, and ®nally oral opioids [65] . A trial of intrathecal steroids could be discussed in patients who do not respond to any treatment measures, but whether intrathecal delivery of methylprednisolone alone is safe and effective has not been ascertained in trials.
Conclusion
Animal studies have revealed a number of mechanisms that contribute to neuropathic pain. Recent studies have shown conclusively that apart from damaged neurones the properties of non-damaged sensory neurones projecting into damaged can change signi®cantly. However, the relative importance of these mechanisms has neither been fully established in animal models nor is it clear how these changes contribute to the generation of pain in humans. Therapy of neuropathic pain is still limited and oral treatment includes tricyclic antidepressants, gabapentin and opioids. The ef®cacy of carbamazepine and phenytoin is unclear and is probably overestimated. The ef®cacy of sodium channel blockers such as mexiletine or lamotrigine and of NMDA-antagonists such as dextromethorphan or memantine is low and the clinical use of these drugs is hampered by profound sideeffects. Neurokin 1 antagonist appears to be ineffective. 1115±1121. Patients with restless legs syndrome can be divided into two major groups: a younger group with a family history and no pain and an older group with dysaesthesia and no family history. Using skin biopsies, this study shows that approximately one-third of patients with restless legs syndrome have a neuropathy that is found mainly in the second group. RC140. This study shows that uninjured cutaneous nociceptors develop some low level of ongoing discharge after lesion to a spinal nerve. Using local anaestheic blocks it is shown that this ectopic activity arises from the terminal endings in the skin.
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